Want to see AYTU full AI Analyst Report?
AYTU Stock Chart & Stats
$2.16
$0.00(0.00%)
At close: 4:00 PM EDT
$2.16
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.65 - $3.07
Previous Close$2.16
Volume10.41K
Average Volume (3M)21.99K
Market Cap
$23.08M
Enterprise Value$24.92
Total Cash (Recent Filing)$26.71M
Total Debt (Recent Filing)$22.94M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Sep 29, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.29
Shares Outstanding10,733,208
10 Day Avg. Volume15,294
30 Day Avg. Volume21,988
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-2.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.50Price Target Upside339.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$70.63M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt-to-equity (~0.05) provides durable financial flexibility, lowering interest burden and refinancing risk. This conservative leverage profile helps the company fund launch investments and absorb operating losses in the near term without heavy reliance on new debt financing.
Improving Cash GenerationTrailing twelve‑month operating and free cash flow turned positive, indicating an early improvement in cash conversion versus prior periods. While still small relative to revenue, consistent FCF would materially reduce financing dependence and support continued commercial investment over the next several quarters.
New Product Unit Economics & Early TractionEXXUA's reported early commercial traction plus attractive unit economics (low COGS and targeted mid‑to‑high‑60% gross margins) create a credible path to durable margin improvement as scale builds. Combined with RxConnect access metrics, these structural features can drive sustainable contribution as adoption expands.
Bears Say
Declining Revenue TrendRevenue contraction on a trailing‑twelve‑month basis signals structural headwinds from legacy portfolio erosion and payer dynamics. Sustained top‑line declines reduce operating leverage, making it harder for a growing product to offset lost legacy sales and to achieve durable profitability within a 2–6 month horizon.
Large Ongoing LossesVery wide negative net margins and continuing operating losses materially erode shareholder returns and equity cushions over time. Persistent losses increase the need for external funding or rapid scale‑up of profitable products and make the company's financial position vulnerable if new product growth slips.
Branded Portfolio Pressure From GenericsThe emergence of an authorized generic taking share is a structural revenue threat to the ADHD franchise and contributed to inventory write‑downs and gross‑to‑net volatility. This intensifies dependence on EXXUA scaling to replace durable revenue, raising execution and reimbursement risk over the medium term.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience’s price range in the past 12 months?
Aytu BioScience lowest stock price was $1.65 and its highest was $3.06 in the past 12 months.
What is Aytu BioScience’s market cap?
Aytu BioScience’s market cap is $23.08M.
When is Aytu BioScience’s upcoming earnings report date?
Aytu BioScience’s upcoming earnings report date is Sep 29, 2026 which is in 58 days.
How were Aytu BioScience’s earnings last quarter?
Aytu BioScience released its earnings results on May 13, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.443 by -$0.087.
Is Aytu BioScience overvalued?
According to Wall Street analysts Aytu BioScience’s price is currently Undervalued.
Does Aytu BioScience pay dividends?
Aytu BioScience does not currently pay dividends.
What is Aytu BioScience’s EPS estimate?
Aytu BioScience’s EPS estimate is -0.29.
How many shares outstanding does Aytu BioScience have?
Aytu BioScience has 10,733,208 shares outstanding.
What happened to Aytu BioScience’s price movement after its last earnings report?
Aytu BioScience reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.443. Following the earnings report the stock price went up 0.889%.
Which hedge fund is a major shareholder of Aytu BioScience?
Currently, no hedge funds are holding shares in AYTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aytu BioScience
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
AYTU Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: EXXUA's initial commercial launch shows strong early traction with accelerating prescription and shipment trends, encouraging payer coverage and attractive unit economics, and the RxConnect program appears to be reducing access friction. Offsetting this are significant year-over-year declines in legacy revenue, a quarter with a net loss and negative adjusted EBITDA, an inventory write-down, and near-term gross-to-net and cash-use volatility while the launch investment continues. Given the early-stage but tangible commercial progress balanced against meaningful near-term financial headwinds, the tone is cautiously optimistic but still transitional.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.50
▲(339.81% Upside)
Technical Analysis
Ownership Overview
5.21% Insiders
3.42% Mutual Funds
<0.01% Other Institutional Investors
88.80% Public Companies and
Individual Investors